-- Max Resource (MAX.V) 週四宣布，已申請在美國OTCQB市場上市。 該公司表示，其股票將繼續在多倫多證券交易所創業板（TSX Venture Exchange）以現有股票代碼進行交易。 該公司的OTCQB上市申請尚需OTC Markets的審核和批准。 該公司補充道，其股票符合透過存託信託公司（DTC）進行結算的條件，DTC負責美國上市公司的電子清算和結算。 執行長Brett Matich表示：“我們相信，在OTCQB上市將擴大Max在美國投資者中的影響力，提高交易的便利性和流動性，並有助於公司在勘探季全面展開之際，拓展更廣泛的國際股東基礎。” 截至發稿時，該公司股票在TSX Venture Exchange的股價下跌0.025美元，至0.28美元。
Price: $0.28, Change: $-0.03, Percent Change: -8.20%
HawkEye 360 (HAWK) shares rose nearly 30% in their New York Stock Exchange debut Thursday.The stock opened at $33.80 per share, higher than the initial public offering price of $26 per share.The company priced its IPO of 16 million shares for gross proceeds of about $416 million. The offering is expected to close Friday.Price: $33.77, Change: $+7.77, Percent Change: +29.88%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our target by $33 to $317, 24x our 2026 EPS estimate and in line with the shares' ten-year average forward multiple. We lower our 2026 EPS view to $13.21 from $13.44 and 2027's to $14.11 from $14.27. We upgrade MCD from Hold to Buy. Shares trade at a 12% discount to their ten-year forward average, creating an attractive entry point despite near-term margin headwinds from restaurant operating costs, particularly beef costs. We expect margin normalization as traffic gains scale and value messaging matures. Q1 results outperformed on total revenue, global comps, and adjusted EPS, with developed market comps of +3.9%, improving 490 bps sequentially, and developing markets maintaining momentum at +3.4%. In our view, results suggest value positioning is resonating globally and driving traffic recovery. MCD's category expansion into chicken and beverages provides incremental growth optionality, while >80% free cash flow conversion supports continued investment in restaurant development and shareholder returns.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target price at $19, which is 16.5x our 2027 EPS view of $1.15, a discount to the trading multiple of 18.1x since going public in 2023. We think this multiple is justified given the litigation overhang and limited visibility into KVUE's standalone performance (the company is no longer providing forward-looking guidance and hosting an analyst call) due to the pending acquisition by Kimberly-Clark (KMB), expected to close during 2H 2026. We increase our 2026 EPS estimate to $1.15 from $1.10 following this morning's Q1 earnings release. We maintain our 2027 EPS estimate at $1.15. Kenvue delivered a solid first quarter that demonstrated continued operational momentum. Net sales increased to $3,909M (+4.5% Y/Y) with organic growth of 0.7%. The performance suggests management's operational initiatives are gaining traction as the company approaches the transaction close. The transaction received shareholder approval in January 2026, and regulatory approvals are progressing.